In the last 2 years, literature data have shown that variations in protocadherin 12 (PCDH12) gene are related to neurological outcomes. Located at chromosome 5q31, this gene encodes the PCDH12 protein, wich is part of the cadherin superfamily and it is a calcium-dependent cell-adhesion protein. The role of PCDH12 is not yet fully understood in the brain, but evidence shows the importance of nonclustered protocadherins for the normal development of the central nervous system [1].

In a recent publication in this journal, Suzuki-Muromoto et al. reported a case of a Japanese patient with dyskinetic cerebral palsy, intellectual disability and epilepsy, born to non-consanguineous parents, with two heterozygous variations in the PCDH12 gene, a different pattern from the other cases already described [2]. The first work that showed a relation of a variation in the PCDH12 gene with neurological outcomes was published by Aran et al., where Palestinian patients from consanguineous families, developed pre- and postnatal damages, with a pseudo-TORCH pattern, from a single homozygous nonsense variation [3]. The homozygous variation described, occurred in the cytoplasmic domain of the PCDH12 protein, while the double heterozygous variation occurred in the extracellular domain (Fig. 1).

Fig. 1
figure 1

Distribution of variations along the PCDH12 gene. The numbers in brackets identify the reference number

Knockout mice for the PCDH12 gene are alive and fertile, but, present alterations in the placenta in relation to their morphogenesis, vascularization and transcriptional levels of 2289 genes, contributing to a reduced embryo size and abnormal lens morphology [4]. Different from that reported in humans, in mice, only the homozygous variation is able to develop phenotypes harmful to the animal, heterozygous variation did not cause any harmful consequences.

In humans, the condition of two heterozygous variations did not result in intrauterine growth retardation, microcephaly and visual impairment, clinical findings of patients with homozygous variation. Other neurological findings are shared among patients with variations in the PCDH12 gene, regardless of the mutation pattern, such as cerebral calcification and epilepsy. Spot calcifications in perithalamic regions are found in some patients already reported, but other areas, particularly in each patient described, also had a spot calcification, such as subcortical regions and posterior limb of internal capsule [5]. Figure 1 also shows heterozygous variants, with no clear causative role, found in some elder subjects with primary brain calcification, presenting with late and variable manifestations such as dementia and gait impairment.

The brain has a very low expression of PCDH12 [6], therefore, the amount of negative effects that happens when this gene is mutated calls attention. Although there are few cases reporting variations of this gene, what is perceived is that the mutation pattern seems to influence the expression of certain phenotypes and consequent severity of the patient. As already discussed here and as can be seen in table 1 of the article by Suzuki-Muromoto et al. (2018), in general, homozygous variation seems to be more damaging to the patient, especially in relation to the development and onset of seizures.

The evaluation of transcript expression of PCDH12 would bring more data to increase discussion and knowledge of the impact of two heterozygous variants in the described patient. The patient is the fourth child of healthy parents, and for a better description of the finding, a family segregation analysis would be an important contribution to the study of the variations of this gene. Beyond the mutation pattern, environmental factors should also be considered for future analysis of the differences between the phenotypes developed by the patients.

In conclusion, the identification of a new mutation pattern of the PCDH12 gene, brings to light new clinical findings that may help better understanding the role of this gene in the central nervous system. His role is still intriguing, mainly because it is related to distinct brain areas and the development of diverse clinical findings. The use of animal models presents a good opportunity for the understanding of this gene, models that already exist and that need to be more explored from the neurological point of view, pre- and postnatal.